Tax-independent stimulation of human T-cell leukemia virus type-I expression and differential effects on its infectivity by subtoxic and toxic doses of 3-methylcholanthrene.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Tax-independent stimulation of human T-cell leukemia virus type-I expression and differential effects on its infectivity by subtoxic and toxic doses of 3-methylcholanthrene.

Cell Mol Biol Res. 1995;41(5):377-85. Unique Identifier : AIDSLINE MED/97021424
Revazova T; Dombrovsky A; Lochelt M; Flugel RM; Aboud M; Department of Microbiology and Immunology, Ben Gurion University of; the Negev, Beer Sheva, Israel.

Abstract: Using the human T-cell leukemia virus type I (HTLV-I) infected SLB-I T-cell line, we showed in this study that 5-d treatment with the maximal subtoxic 3-methylcholanthrene (3-MC) dose (0.25 microgram/ml), as well as with a 3-MC dose that inhibits 50% of the cell growth (5 micrograms/ml), profoundly increased the level of viral RNA. Exposure to these 3-MC doses for 5 d before transient transfection of HTLV-I LTR-CAT construct into these cells markedly stimulated CAT activity, indicating that 3-MC exerted its effect by a trans-acting mechanism. A similar stimulation was observed when this construct was transfected into 3-MC treated uninfected Jurkat cells, indicating that this trans-acting effect was independent of the viral tax protein. However, although the subtoxic 3-MC dose increased also the capacity of SLB-I cells to transmit the virus to normal peripheral blood lymphocytes in coculture, the toxic dose strongly reduced this capacity. No inhibition by this toxic dose was observed in the viral protein synthesis or processing nor in the final release of the virus from the cells. However, the virions released under the influence of this 3-MC dose were found to contain mainly the uncleaved gag precursor polypeptide and a low level of reverse transcriptase. Thus, the reduced virus transmission capacity of the host cells can be ascribed to this structural defect, which presumably lowered the viral infectivity.

Keywords: *Carcinogens/PHARMACOLOGY *Gene Expression Regulation, Viral/DRUG EFFECTS *HTLV-I/DRUG EFFECTS *HTLV-I/GROWTH & DEVELOPMENT *Methylcholanthrene/PHARMACOLOGY
970730
M9772129

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .